Since 2019, three disease-specific therapies have been approved to treat patients with ATTR-CM. The first was Pfizer’s Vyndamax (tafamidis) in May 2019, which was approved for both wild type and ...

NTLA shares plunge 55% in three months after the FDA placed a clinical hold on Nex-Z, suspending trials and milestone guidance following the death of a patient.

The global amyloidosis treatment market is on a trajectory of significant expansion, driven by heightened disease awareness, ...

Beam Therapeutics BEAM is engaged in developing investigational gene therapy candidates that are currently in ...

Background Amyloid transthyretin (ATTR) amyloidosis is a rare, life-threatening disease frequently manifesting with ...

The stock has lost significant market value since that debacle. While it's not clear that nex-z was responsible, it's also not clear that it wasn't. Until the medicine receives clearance from the U.S.

Lindsay Curtis is a health & medical writer in South Florida. She worked as a communications professional for health nonprofits and the University of Toronto’s Faculty of Medicine and Faculty of ...

Detailed price information for Immix Biopharma Inc (IMMX-Q) from The Globe and Mail including charting and trades.

Beyond premiering a first album in 16 years on release day, this show was special because of its scale. Albeit the Troxy holds 3,000, The Cure’s typical habitat has long been sports stadia and outdoor ...